PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 144 filers reported holding PROGENICS PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 0.54 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $21,832,000 | -24.8% | 5,745,266 | +0.7% | 0.00% | 0.0% |
| Q4 2019 | $29,033,000 | +1.6% | 5,703,951 | +0.9% | 0.00% | 0.0% |
| Q3 2019 | $28,578,000 | -15.2% | 5,653,361 | +3.5% | 0.00% | 0.0% |
| Q2 2019 | $33,712,000 | +42.5% | 5,463,704 | +7.2% | 0.00% | 0.0% |
| Q1 2019 | $23,659,000 | +58.3% | 5,098,901 | +43.3% | 0.00% | 0.0% |
| Q4 2018 | $14,941,000 | -52.8% | 3,557,587 | -29.5% | 0.00% | 0.0% |
| Q3 2018 | $31,641,000 | -8.9% | 5,046,431 | +16.8% | 0.00% | 0.0% |
| Q2 2018 | $34,723,000 | +15.2% | 4,318,856 | +6.9% | 0.00% | 0.0% |
| Q1 2018 | $30,140,000 | +24.5% | 4,040,195 | -0.7% | 0.00% | 0.0% |
| Q4 2017 | $24,213,000 | -24.7% | 4,069,600 | -6.9% | 0.00% | -50.0% |
| Q3 2017 | $32,170,000 | +10.2% | 4,371,021 | +1.6% | 0.00% | +100.0% |
| Q2 2017 | $29,200,000 | -25.2% | 4,300,478 | +4.1% | 0.00% | -50.0% |
| Q1 2017 | $39,013,000 | +59.7% | 4,132,770 | +46.1% | 0.00% | +100.0% |
| Q4 2016 | $24,436,000 | +38.9% | 2,828,283 | +1.8% | 0.00% | 0.0% |
| Q3 2016 | $17,594,000 | +52.3% | 2,779,477 | +1.5% | 0.00% | 0.0% |
| Q2 2016 | $11,552,000 | +6.1% | 2,737,391 | +9.7% | 0.00% | 0.0% |
| Q1 2016 | $10,883,000 | -25.2% | 2,496,164 | +5.1% | 0.00% | 0.0% |
| Q4 2015 | $14,553,000 | +8.7% | 2,374,125 | +1.5% | 0.00% | – |
| Q3 2015 | $13,384,000 | -20.9% | 2,339,901 | +3.2% | 0.00% | -100.0% |
| Q2 2015 | $16,911,000 | +27.3% | 2,266,922 | +2.1% | 0.00% | 0.0% |
| Q1 2015 | $13,280,000 | -16.1% | 2,220,768 | +6.0% | 0.00% | 0.0% |
| Q4 2014 | $15,836,000 | +47.9% | 2,094,767 | +1.6% | 0.00% | 0.0% |
| Q3 2014 | $10,704,000 | +29.2% | 2,062,588 | +7.3% | 0.00% | 0.0% |
| Q2 2014 | $8,282,000 | +9.1% | 1,921,462 | +3.5% | 0.00% | 0.0% |
| Q1 2014 | $7,590,000 | -2.9% | 1,855,798 | +26.5% | 0.00% | 0.0% |
| Q4 2013 | $7,818,000 | +3.2% | 1,466,967 | -2.6% | 0.00% | 0.0% |
| Q3 2013 | $7,573,000 | +35.1% | 1,505,498 | +19.8% | 0.00% | 0.0% |
| Q2 2013 | $5,605,000 | – | 1,256,684 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |